New Academic CD19 CAR-T ARI-0001 Ph2 Trial in R/R ALL Posted

On Wednesday, March 3, a new ARI-0001 (autologous CD19 CAR-T) Ph2 trial (CART19-BE-02) was observed on CT.gov for the treatment of adult r/r ALL. Below, Celltelligence provides details for this trial and how ARI-0001’s point-of-care (PoC) model could potentially be replicated in other countries if proven successful.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.